Can Cystectomy Be Avoided? Exploring the Implications of the RETAIN 1 Trial

In this video, Daniel M. Geynisman, MD, of Fox Chase Cancer Center, discusses a critical finding from the phase 2 RETAIN 1 trial: a 68% recurrence rate among patients in the active surveillance group. Dr. Geynisman shares valuable insights into what these recurrences reveal about the feasibility of cystectomy-sparing approaches in muscle-invasive bladder cancer and how to refine patient selection for bladder preservation. Dr. Geynisman also highlights the importance of future research, including results from the RETAIN 2 trial, which will explore these approaches further and will be presented at ASCO GU 2025.